Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine Dose Escalation in Chronic Spontaneous Urticaria
NCT02213367Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bilastine in chronic spontaneous urticaria (CSU) (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Disease Activity (UAS7) at 8 weeks. Started Jul 2014; status: completed.
02
Drugs
bilastine
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT02213367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213367.